echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca terminates development of Phase II/III COVID-19 vaccine AZD2816

    AstraZeneca terminates development of Phase II/III COVID-19 vaccine AZD2816

    • Last Update: 2022-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    AstraZeneca disclosed in its 2021 financial report that it has terminated the development of the new coronary pneumonia vaccine AZD2816



    Mene Pangalos, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca, said: "AZD2816 is not significantly different in immunogenicity from the marketed vaccine Vaxzevria and there is no need to switch from one vaccine to another



    Vaxzevria uses replication-defective simian adenovirus ChAdOx1 as a vector, containing the full-length spike protein of SARS-CoV-2 and a TPA leader sequence



    AZD2816 is an improved vaccine against the Beta variant, developed using the same adenoviral vector technology platform as Vaxzevria



    In addition, AstraZeneca has also deployed a long-acting antibody cocktail therapy Evusheld (tixagevimab + cilgavimab) in the field of new coronary pneumonia



    This is a wake-up call for Moderna and Pfizer


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.